BCL-2 is dispensable for thrombopoiesis and platelet survival

Navitoclax (ABT-263), an inhibitor of the pro-survival BCL-2 family proteins BCL-2, BCL-X(L) and BCL-W, has shown clinical efficacy in certain BCL-2-dependent haematological cancers, but causes dose-limiting thrombocytopaenia. The latter effect is caused by Navitoclax directly inducing the apoptotic...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cell Death Dis
Main Authors: Debrincat, M A, Pleines, I, Lebois, M, Lane, R M, Holmes, M L, Corbin, J, Vandenberg, C J, Alexander, W S, Ng, A P, Strasser, A, Bouillet, P, Sola-Visner, M, Kile, B T, Josefsson, E C
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2015
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4650559/
https://ncbi.nlm.nih.gov/pubmed/25880088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2015.97
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki